|
|
| | Paquinimod Basic information |
| Product Name: | Paquinimod | | Synonyms: | Paquinimod;ABR?215757;N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide;ABR 25757;ABR 25757;ABR-25757;ABR25757;PAQUINIMOD;248282-01-1;ABR25757;ABR-25757;ABR?215757; ABR 215757; ABR215757; PAQUINIMOD. | | CAS: | 248282-01-1 | | MF: | C21H22N2O3 | | MW: | 350.41 | | EINECS: | | | Product Categories: | | | Mol File: | 248282-01-1.mol |  |
| | Paquinimod Chemical Properties |
| Boiling point | 487.3±45.0 °C(Predicted) | | density | 1.267±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO:15.0(Max Conc. mg/mL);42.8(Max Conc. mM) | | form | A solid | | pka | 4.50±1.00(Predicted) |
| | Paquinimod Usage And Synthesis |
| Uses | Paquinimod is a S100A9 inhibitor preventing S100A9 binding to TLR-4. Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Paquinimod treatment of collagenase-induced OA (CIOA) resulted in significantly reduced synovial thickening (57%), osteophyte size at the medial femur (66%) and cruciate ligaments (67%) and cartilage damage at the medial tibia (47%) and femur (75%; n=7, untreated n=6). Paquinimod reduces leukocyte recruitment during sterile inflammation. Paquinimod also reduced priming of proinflammatory effector CD4(+) T cells. |
| | Paquinimod Preparation Products And Raw materials |
|